Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a ferruginine compound or a anhydroecgonine compound.

Abstract: A method of attenuating the symptoms of opioid withdrawal in a human or animal subject comprises administering to the subject an effective opioid withdrawal symptom attenuating amount of an inhibitor of nitric oxide synthase (NOS) for a period of time effective to attenuate such symptoms upon opioid withdrawal. NOS inhibitors useful in the present method include, for example, L-N.sup.G -nitroarginine, esters of L-N.sup.G -nitroarginine, L-N.sup.G -monomethylarginine, L-N.sup.G -benzylarginine, L-N.sup.G -aminoarginine, iminoethylornithine, and pharmaceutically acceptable salts thereof. These compounds can be used alone or in combination, in conjunction with conventional drugs, such as .alpha..sub.2 -adrenoceptor agonists, mixed agonist-antagonist opioids, and NMDA antagonists, to attenuate the symptoms of opioid withdrawal. Effective doses of NOS inhibitors range from about 1 .mu.g/kg/day to about 30 mg/kg/day, administered over the course of about 1 hour to about six days, followed by opioid withdrawal.

Abstract: The invention relates to the use of compounds of the formula ##STR1## in which p is 2 and q is 1 or p is q and q is 2; Ar represents an optionally substituted phenyl, and Z represents NR.sub.1 R.sub.2 in which R.sub.1 and R.sub.2, which may be identical or different, represent H or optionally substituted alkyl or, with the nitrogen atom, form a saturated heterocycle, or Z represents OR in which R is H or optionally substituted alkyl, or their addition salts, in the form of pure enantiomer or of mixtures thereof, for administration in a human patient for preventing or treating pathologies involving or dependent upon a neovascularization.

Abstract: A method for treating habit disorders in a human patient comprising administering to the patient an anti-habitual amount of a pharmaceutically active compound, which results in activation of a brain reward system, e.g., flupenthixol, or esters thereof or pharmaceutically acceptable salts thereof, either alone or in admixture with a physiologically acceptable diluent.

Abstract: The invention relates to the use of compounds of formula (I) ##STR1## wherein Im represents an imidazolyl group of formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 (wherein R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.5 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.5 or --SO.sub.2 R.sup.5);one of the groups represented by R.sup.2, R.sup.3 and R4 is a hydrogen atom or a C.sub.

Abstract: Efficacious phenol-free mycobactericidal liquid compositions having low odor and irritation potential are disclosed. These compositions consist of a solvent containing a glycol, a 2 to 6 carbon atom aldehyde, specific anionic surfactants, and buffer salts to stabilize the pH in the 6 to 7.4 range. The ratio of glycol to aldehyde is comprised between 0.1 and 6.0. The lower this ratio, the greater the mycobactericidal activity. The new odorless compositions can kill Mycobacterium tuberculosis (EPA quantitative procedure) in 10 minutes or less at 20.degree. C.

Abstract: An improved process for employing tricyclic antidepressants involving co-administration of a N-benzyl-pyrrolidin-2-one.

Abstract: A method is provided for treating multiple sclerosis by administering to a subject afflicted with that disease a symptom-alleviating amount of a compound selected from the group consisting of phytic acid, mixed counterion phytate salt, an isomer or hydrolysate of phytic acid or mixed counterion phytate salt, a mixture of any combination thereof, or with one or more dephosphorylating enzymes. The preferred method of administration is by oral dosages of about 1/2 to 3 grams/kilogram bodyweight per day.

Abstract: A method of inhibiting cell proliferation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition comprising, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutically acceptable salt thereof, which is a substituted styrene compound which can also be a naphthalene, an indane or a benzoxazine; including nitrile and molononitrile compounds, and pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of such compound.

Abstract: The stability of compositions of choline salicylate-metal salicylate-carboxymethylcellulose is improved by the incorporation therein of microcrystalline cellulose. The microcrystalline cellulose is linked to the remainder of the composition by liquid bridges and is preferably present in an amount of about 2.5-25% by weight. The microcrystalline cellulose enhances the stability of the composition and thereby enhances solid dosage forms thereof such as tablets, capsules, suppositories and granules.

Abstract: The invention relates to the use of L-tryptophane and a peripheral degradation inhibitor for L-tryptophan for the preparation of an analgesic drug for humans, the ratio by weight of L-tryptophan to the peripheral degradation inhibitor being from 3:1 to 10:1.

Abstract: Disclosed herein are analgesic copper coordination compounds and a process for using them in the treatment of analgesia in animal bodies. The copper coordination compounds utilized are the reaction products of copper salts with:1. carboxylic acids or their alkaline earth salts;2. aromatic carboxylic acids or their alkaline earth salts;3. heterocyclic carboxylic acids or their alkaline earth salts;4. amino acids or their alkaline earth salts;5. anthranilic acids or their alkaline earth salts;6. salicylic acids or their alkaline earth salts;7. acetylsalicylates or their alkaline earth salts;8. arylacetic acids or their alkaline earth salts;9. disubstituted aminodithiocarbamates, and mixtures of any of the above.The process disclosed comprises administering to animals, orally or parenterally, in controlled dosages, the aforementioned copper coordination compounds.

Abstract: A halogen-substituted diphenylsufide compound is disclosed which produce a large selective inhibition of serotonin uptake in brain. This compound is useful in the treatment of depression as well as anxiety, obsessive compulsive disorders and alcoholism.

Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a pyridylalkylpiperidine compound or a pyridylalkylpyrrolidine compound.

Abstract: The present invention encompasses methods of using 5-phenyl-2-furan esters, amides and ketones and compositions thereof to prevent or limit neuronal death or degeneration in a human or lower animal. These methods comprise systemically administering to such human or other animal a safe and effective amount of a compound of the formula: ##STR1## wherein (1) X is halo or hydrogen, and Y is a substituent selected from the group consisting of unsubstituted or halogen-substituted methyl, halo, nitro, amino, and methoxy; and(2) R is R.sup.1 C(0)OH, R.sup.1 C(0)N(R.sup.3).sub.2, N(R.sup.3).sub.2, OR.sup.1 N(R.sup.3).sub.2, R.sup.1 N(R.sup.3).sub.2, N(R.sup.2)R.sup.1 N(R.sup.3).sub.2, or N(R.sup.2)N(R.sup.3).sub.2 ; whereR.sup.1 is C.sub.1 -C.sub.3 alkyl which is unsubstituted or substituted with C.sub.1 -C.sub.2 alkyl;R.sup.2 is hydrogen or lower alkyl; andeach R.sup.3 is, independently, hydrogen or lower alkyl; orboth R.sup.

Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a meta-nicotine compound.

Abstract: Pharmaceutical compositions containing aromatic 2-benzazepines with fused 5- or 6-membered heterocyclic rings are disclosed which are useful in the treatment of panic disorder or anxiety disorder.

Abstract: The invention concerns a method for treating pain and/or CNS disorders characterized in that the method uses a compound which acts selectively as an antagonist of gamma aminobutyric acid (GABA) at GABA autoreceptors relative to GABA.sub.A receptors.

Abstract: The invention provides an analgesic cream containing ibuprofen with superior skin penetration properties obtained in part by maintaining a pH of 4 to 7.2 such that the ibuprofen is suspended in substantially solid crystalline form.

Abstract: Substituted imidazoles such as 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxy methyl)imidazole and 2-butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imi dazole and pharmaceutically acceptable salts thereof are useful for treating chronic renal failure, mediated by angiotensin-II.